Legal & General Group Plc Has $15.86 Million Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Legal & General Group Plc lessened its stake in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 12.1% in the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 128,774 shares of the specialty pharmaceutical company’s stock after selling 17,694 shares during the quarter. Legal & General Group Plc owned about 0.21% of Jazz Pharmaceuticals worth $15,859,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. HighTower Advisors LLC boosted its holdings in shares of Jazz Pharmaceuticals by 37.2% during the third quarter. HighTower Advisors LLC now owns 7,594 shares of the specialty pharmaceutical company’s stock worth $851,000 after acquiring an additional 2,060 shares during the period. Public Employees Retirement System of Ohio acquired a new position in Jazz Pharmaceuticals in the 3rd quarter valued at $2,491,000. Barclays PLC increased its position in Jazz Pharmaceuticals by 19.1% during the 3rd quarter. Barclays PLC now owns 39,210 shares of the specialty pharmaceutical company’s stock worth $4,369,000 after buying an additional 6,289 shares during the period. Coldstream Capital Management Inc. lifted its holdings in shares of Jazz Pharmaceuticals by 7.7% during the third quarter. Coldstream Capital Management Inc. now owns 2,300 shares of the specialty pharmaceutical company’s stock worth $259,000 after buying an additional 165 shares in the last quarter. Finally, Sanctuary Advisors LLC boosted its position in shares of Jazz Pharmaceuticals by 502.8% in the third quarter. Sanctuary Advisors LLC now owns 11,754 shares of the specialty pharmaceutical company’s stock valued at $1,310,000 after acquiring an additional 9,804 shares during the period. Institutional investors own 89.14% of the company’s stock.

Insider Buying and Selling

In other Jazz Pharmaceuticals news, EVP Neena M. Patil sold 3,800 shares of the business’s stock in a transaction on Thursday, February 27th. The shares were sold at an average price of $144.87, for a total transaction of $550,506.00. Following the sale, the executive vice president now owns 33,318 shares of the company’s stock, valued at approximately $4,826,778.66. The trade was a 10.24 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Bruce C. Cozadd sold 1,500 shares of the stock in a transaction on Tuesday, April 1st. The shares were sold at an average price of $123.75, for a total value of $185,625.00. Following the completion of the transaction, the chief executive officer now owns 440,307 shares of the company’s stock, valued at $54,487,991.25. The trade was a 0.34 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 28,736 shares of company stock worth $4,023,305 in the last three months. 4.20% of the stock is owned by corporate insiders.

Jazz Pharmaceuticals Stock Up 1.2 %

JAZZ stock opened at $101.75 on Tuesday. The firm has a 50-day moving average price of $129.28 and a 200-day moving average price of $122.70. Jazz Pharmaceuticals plc has a 12 month low of $95.49 and a 12 month high of $148.06. The company has a current ratio of 4.26, a quick ratio of 3.74 and a debt-to-equity ratio of 1.46. The stock has a market capitalization of $6.18 billion, a P/E ratio of 14.33, a price-to-earnings-growth ratio of 1.04 and a beta of 0.42.

Analyst Ratings Changes

A number of equities analysts recently commented on the stock. UBS Group raised shares of Jazz Pharmaceuticals from a “neutral” rating to a “buy” rating and raised their price target for the stock from $145.00 to $179.00 in a research report on Friday, March 7th. Piper Sandler reiterated an “overweight” rating and issued a $176.00 price target (up from $163.00) on shares of Jazz Pharmaceuticals in a research report on Wednesday, February 26th. JPMorgan Chase & Co. increased their price target on Jazz Pharmaceuticals from $200.00 to $209.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 26th. Barclays restated an “overweight” rating and set a $200.00 price objective (up previously from $190.00) on shares of Jazz Pharmaceuticals in a research note on Thursday, February 27th. Finally, Royal Bank of Canada cut their target price on Jazz Pharmaceuticals from $179.00 to $178.00 and set an “outperform” rating for the company in a research report on Wednesday, February 26th. One equities research analyst has rated the stock with a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Jazz Pharmaceuticals has a consensus rating of “Buy” and an average target price of $187.71.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.